Şizofreni Hastalarında Diyetle Yağ Asidi ve Antioksidan Vitamin Alımlarının Değerlendirilmesi

Amaç: Şizofrenide artan morbidite ve mortalite yetersiz ve dengesiz diyet seçimleri gibi sağlıksız yaşam biçimleriyle ilişkili olabilir. Şizofreni hastalarının diyetle yağ asitleri ve antioksidan vitamin alımlarının yetersiz olup olmadığı ve bu durumun gözlemlenen eksikliklere katkıda bulunup bulunmadığına dair az sayıda çalışma bulunmaktadır. Bu çalışmanın amacı şizofreni hastalarında bazı yağ asidi ve antioksidan vitamin alımlarının saptanması ve sağlıklı kontrollerle karşılaştırılmasıdır. Bireyler ve Yöntem: Çalışma DSM-IV tanı kriterine göre şizofreni ya da şizoaffektif bozukluk tanısı almış 148 hasta ile yaş, cinsiyet yönünden eşleştirilmiş 77 sağlıklı kontrol üzerinde yürütülmüştür. Sosyodemografik veriler ve klinik bilgiler yüzyüze görüşme ile anket aracılığıyla toplanmıştır. Antropometrik ölçümleri ile birlikte besin ögesi alımları geriye dönük 24 saatlik besin tüketim kaydı yardımıyla alınmıştır. Bulgular: Şizofreni hastalarında toplam yağ, doymuş yağ ve tekli doymamış yağ asitleri alımları sağlıklı kontrollerden yüksek bulunmuştur (p

Evaluation of Dietary Fatty Acid and Antioxidant Vitamin Intakes in Schizophrenia Patients

Aim: High morbidity and mortality in schizophrenia may be attributed to an unhealthy lifestyle such as inadequate and unbalanced nutrition. There are few studies in schizophrenia patients whether intake of dietary fatty acids and antioxidant vitamins are inadequate and contribute observed deficits. Subjects and Methods: The study was conducted on 148 individuals diagnosed as having schizophrenia or schizoaffective disorder by the criteria of Diagnostic and Statistical Manual of Mental Disorders (DSM-IV,) and 77 age, gender matched healthy controls. Socio-demographic data and current medications were obtained through interviews and questionnaires. Anthropometric measurements were performed. Food and beverage intake were recorded by using a 24-hour dietary record. Results: Total fat and saturated fatty acid intake was significantly higher in schizophrenia patients than in controls (p<0.05). Although there is no differences were found in omega-6/omega-3 ratio, mean omega-6/omega-3 ratio was 16.2:1 in schizophrenia patients. Beta-carotene and C intakes were significantly lower in schizophrenia patients than in controls (p<0.05). Conclusion: It is needed the development of special dietary interventions for schizophrenia patients as increased intake of dietary fat and low antioxidant vitamin intake may contribute to the development of serious medical comorbidities and increase the metabolic side effects of antipsychotic treatment.

___

  • 1. Stillwell W. Membrane lipids: fatty acids. In: Stillwell W, editors. An Introduction to Biological Membranes. 2nd ed. Elsevier Science; 2016. p. 49-62.
  • 2. Peet M. Nutrition and schizophrenia: beyond omega-3 fatty acids. Prostaglandins Leukot Essent Fatty Acids 2004;70(4):417-422.
  • 3. Yao JK, Stanley JA, Reddy RD, Keshevan MS, Pettegrew JW. Correlations between peripheral polyunsaturated fatty acid content and in vivo membrane phospholipid metabolites. Biol Psychiatry 2002;52:823-830.
  • 4. Assies J, Lieverse R, Vreken P, Wanders RJ, Dingemans PM, Linszen DH. Significantly reduced docosahexaenoic and docosapentaenoic acid concentrations in erythrocyte membranes from schizophrenic patients compared with a carefully matched control group. Biol Psychiatry 2001;49(6):510-522.
  • 5. Fenton WS, Hibbeln J, Knable M. Essential fatty acids, lipid membrane abnormalities, and the diagnosis and treatment of schizophrenia. Biol Psychiatry 2000;47:8- 21.
  • 6. Peet M. Eicosapentaenoic acid in the treatment of schizophrenia and depression: rationale and preliminary double-blind clinical trial results. Prostaglandins Leukot Essent Fat Acids 2003;69(6):477-485.
  • 7. Castillo RI, Rojo LE, Henriquez-Henriquez M, Silva H, Maturana A, Villar MJ, et al. From molecules to the clinic: Linking Schizophrenia and Metabolic Syndrome through Sphingolipids Metabolism. Front Neurosci 2016;10:488.
  • 8. Horrobin DF. The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia. Schizophr Res 1998;30:193- 208.
  • 9. Reddy R, Keshavan M, Yao JK. Reduced plasma antioxidants in first-episode patients with schizophrenia. Schizophr Res 2003;62(3):205-212.
  • 10. Wu JQ, Kosten TR, Zhang XY. Free radicals, antioxidant defense systems, and schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2013;46:200- 206.
  • 11. Soares-Weiser K, Maayan N, McGrath J. Vitamin E for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev 2011;(2).
  • 12. Zhang XY, Zhou DF, Cao LY, Xu CQ, Chen Da C, Wu GY. The effect of vitamin E treatment on tardive dyskinesia and blood superoxide dismutase: a doubleblind placebo-controlled trial. J Clin Psychopharmacol 2004;24(1):83-86.
  • 13. Wainwright P.E. Dietary essential fatty acids and brain function: a developmental perspective on mechanisms. Proc Nutr Soc 2002;61(1):61-69.
  • 14. Lopez SM, Trimbo SL, Mascioli EA, Blackburn GL. Human plasma fatty acid variations and how they are related to dietary intake. Am J Clin Nutr 1991;53:628- 637.
  • 15. Pekcan, G. Beslenme durumunun saptanması. In: Baysal A. editors. Diyet El Kitabı. Hatipoglu Yayinevi. Ankara, 67-141. 2008.
  • 16. Gibson RS. Principles of Nutritional Assessment. Oxford: Oxford University Press; 2005.
  • 17. World Health Organisation. BMI Classification. Available at: http://who.int/bmi/index. jsp?introPage=intro_3.html Accessed November 25, 2016.
  • 18. Merdol Kutluay T. Toplu Beslenme Yapılan Kurumlar İçin Standart Yemek Tarifeleri. Hatipoğlu Yayınevi, Ankara, 2003.
  • 19. Rakıcıoğlu N, Tek Acar N, Ayaz A, Pekcan G. Yemek ve Besin Fotoğraf Kataloğu-Ölçü ve Miktarlar. 2. Baskı. Ata Ofset Matbaacılık, Ankara, 2009.
  • 20. Beslenme Bilgi Sistemleri-(BeBiS ) 6.1 paket programı. (2008). Entwickelt an der Universitat Hohenheim, Stuttgart.
  • 21. Hayran, M. ve Hayran M. Sağlık Araştırmaları İçin Temel İstatistik. Omega Araştırma Organizasyon Eğitim Danışmanlık Ltd. Şti, Ankara, 2011.
  • 22. Brown S, Birtwistle J, Roe L, Thompson C. The unhealthy lifestyle of people with schizophrenia. Psychol Med 1999;29(3):697-701.
  • 23. Ratliff JC, Palmese LB, Reutenauer EL, Liskov E, Grilo CM, Tek C. The effect of dietary and physical activity pattern on metabolic profile in individuals with schizophrenia: a cross-sectional study. Compr Psychiatry 2012;53(7):1028-1033.
  • 24. Ito H, Kumagai T, Kimura M, Koike S, Shimizu T. Dietary intake in body mass index differences in community-based Japanese patients with schizophrenia. Iran J Public Health 2015;44(5):639-645.
  • 25. Strassnig M, Brar JS, Ganguli R. Nutritional assessment of patients with schizophrenia: a preliminary study. Schizophr Bull 2003;29:393-397.
  • 26. Vessby B, Uusitupa M, Hermansen K, Riccardi G, Rivellese AA, Tapsell LC, et al. Substituting dietary saturated for monounsaturated fat impairs insulin sensitivity in healthy men and women: The KANWU Study. Diabetologia 2001;44(3):312-319.
  • 27. Strassnig M, Brar JS, Ganguli R. Dietary fatty acid and antioxidant intake in community-dwelling patients suffering from schizophrenia. Schizophr Res 2005b;76:343-351.
  • 28. Sağlık Bakanlığı Sağlık Araştırmaları Genel Mudürlüğü Hacettepe Üniversitesi Sağlık Bilimleri Fakültesi Beslenme ve Diyetetik Bölümü, Ankara Numune Eğitim ve Araştırma Hastanesi. (2014). Türkiye Beslenme ve Sağlık Araştırması (TBSA)-2010 Beslenme Durumu ve Alışkanlıklarının Değerlendirilmesi Sonuç Raporu. (Rapor No:931). Ankara:T.C. Sağlık Bakanlığı.
  • 29. Horrobin DF. Schizophrenia as a membrane lipid disorder which is expressed throughout the body. Prostaglandins Leukot Essent Fat Acids, 1996;55:3-7.
  • 30. Reddy RD, Keshavan MS, Yao JK. Reduced red blood cell membrane essential polyunsaturated fatty acids in first episode schizophrenia at neuroleptic-naive baseline. Schizophr Bull 2004;30(4):901-911.
  • 31. Mahadik SP, Scheffer RE. Oxidative injury and potential use of antioxidants in schizophrenia. Prostaglandins Leukot Essent Fat Acids 1996;55(1-2):45-54.
  • 32. Simopoulos AP. Human requirement for N-3 polyunsaturated fatty acids. Poult Sci, 2000;79(7):961- 970.
  • 33. World Health Organization Fats and oils in human nutrition: report of a joint expert consultation. Food and Agriculture Organization of the United Nations and the World Health Organization. FAO Food Nutr Pap. 57 (1995), pp. 1-147
  • 34. Emken EA, Adlof RO, Gulley RM. Dietary linoleic acid influences desaturation and acylation of deuteriumlabeled linoleic and ALAs in young adult males. Biochem Biophys Acta 1994;1213:277-288.
  • 35. Masters MC. Fatty acids and the peroxisome. Mol Cell Biochem 1996;165:83-93.
  • 36. Champeil-Potokar G, Denis I, Goustard-Langelier B, Allesandri JM, Guesnet P, Lavialle M. Astrocytes in culture require docosahexaenoic acid to restore the n-3/n-6 polyunsaturated fatty acid balance in their membrane phospholipids. J Neurosci Res 2004;75:96- 106.
  • 37. Prabakaran S, Swatton JE, Ryan MM, Huffaker SJ, Huang JT, Griffin JL, et al. Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress. Mol Psychiatry 2004;9(7):643.
  • 38. Phillips M, Sabas M, Greenberg J. Increased pentane and carbon disulfide in the breath of patients with schizophrenia. J Clin Pathol 1993;46:861-864.
  • 39. Lohr JB. Oxygen radicals and neuropsychiatric illness. Some speculations. Arch Gen Psychiatry 1991;48(12):1097-1106.
  • 40. McCreadie R. Smoking habits and plasma lipid peroxide and vitamin E levels in never-treated firstepisode patients with schizophrenia. Br J Psychiatry 2000;176:290-293.
  • 41. Lohr JB, Kuczenski R, Niculescu AB. Oxidative mechanisms and tardive dyskinesia. CNS Drugs, 2003;17(1):47-62.
  • 42. Jeding I, Evans PJ, Akanmu D, Dexter D, Spencer JD, Aruoma OI, Jenner P, Halliwell B. Characterization of the potential antioxidant and pro-oxidant actions of some neuroleptic drugs. Biochem Pharmacol 1995;49:359-365.
  • 43. Melkersson K, Dahl ML. Adverse metabolic effects associated with atypical antipsychotics: literature review and clinical implications. Drugs, 2004;64(7):701-723.
  • 44. Rivellese AA, Lilli S. Quality of dietary fatty acids, insulin sensitivity and type 2 diabetes. Biomed Pharmacother 2003;57:84-87.
  • 45. Hu FB, van Dam RM, Liu S. Diet and risk of type II diabetes: the role of types of fat and carbohydrate. Diabetologia 2001;44:805-817.
  • 46. Henderson DC, Sharma B, Fan X, Copeland PM, Borba CP, Freudenreich O, et al. Dietary saturated fat intake and glucose metabolism impairments in nondiabetic, nonobese patients with schizophrenia on clozapine or risperidone. Ann Clin Psychiatry 2010;22(1):33-42.
  • 47. Archie SM, Goldberg JO, Akhtar-Danesh N, Landeen J, McColl L, McNiven J. Psychotic disorders, eating habits, and physical activity: who is ready for lifestyle changes? Psychiatr Serv 2007;58(2):233-239.
  • 48. Ryan MC, Collins P, Thakore JH. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry 2003;160:284- 289.
  • 49. Raedler TJ. Cardiovascular aspects of antipsychotics. Curr Opin Psychiatry 2010;23(6):574-581.
  • 50. Uçok A, Gaebel W. Side effects of atypical antipsychotics: a brief overview. World Psychiatry 2008;7(1):58-62.
Beslenme ve Diyet Dergisi-Cover
  • ISSN: 1300-3089
  • Yayın Aralığı: Yılda 3 Sayı
  • Başlangıç: 1972
  • Yayıncı: Türkiye Diyestisyenler Derneği